Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib

The epidermal growth factor receptor (EGFR) is an important therapeutic target in colorectal cancer (CRC). After the initial promising results of EGFR-targeted therapies such as cetuximab, therapeutic resistance poses a challenging problem and limits the success of effective anti-EGFR cancer therapi...

Full description

Bibliographic Details
Main Authors: Ines De Pauw, Filip Lardon, Jolien Van den Bossche, Hasan Baysal, Patrick Pauwels, Marc Peeters, Jan Baptist Vermorken, An Wouters
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:Cancers
Subjects:
afatinib
cetuximab resistance
colorectal cancer
EGFR
HER receptors
Online Access:http://www.mdpi.com/2072-6694/11/1/98

Internet

http://www.mdpi.com/2072-6694/11/1/98

Similar Items